[1]张艳妮,李世玲,邓 春.动脉导管未闭与支气管肺发育不良发生风险相关性的Meta分析[J].医学信息,2023,36(18):33-38.[doi:10.3969/j.issn.1006-1959.2023.18.006]
　ZHANG Yan-ni,LI Shi-ling,DENG Chun.Meta-analysis of the Correlation Between Patent Ductus Arteriosus and the Risk of Bronchopulmonary Dysplasia[J].Journal of Medical Information,2023,36(18):33-38.[doi:10.3969/j.issn.1006-1959.2023.18.006]
点击复制

动脉导管未闭与支气管肺发育不良发生风险相关性的Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年18期
页码:
33-38
栏目:
医学数据科学
出版日期:
2023-09-15

文章信息/Info

Title:
Meta-analysis of the Correlation Between Patent Ductus Arteriosus and the Risk of Bronchopulmonary Dysplasia
文章编号:
1006-1959（2023）18-0033-06
作者:
张艳妮; 李世玲; 邓 春
（重庆医科大学附属永川医院新生儿科，重庆 402160）
Author(s):
ZHANG Yan-ni; LI Shi-ling; DENG Chun
(Department of Neonatology,Yongchuan Hospital Affiliated to Chongqing Medical University,Chongqing 402160,China)
关键词:
动脉导管未闭; 支气管肺发育不良; 早产儿
Keywords:
Patent ductus arteriosus; Bronchopulmonary dysplasia; Premature infant
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2023.18.006
文献标志码:
A
摘要:
目的 阐明动脉导管未闭（PDA）的管径大小是否与早产儿支气管肺发育不良（BPD）的关系。方法 通过检索PubMed、EMbase、CochraneLibrary、Web of Science、CNKI和万方等电子数据库查找PDA与支气管肺发育不良发生风险相关性的文献，检索时限截止至2022年10月。对纳入的文章进行质量评价，计算各比值比（OR）和95%置信区间（95%CI），采用RevMan5.4软件进行数据分析，用I-Square（I2）检验及敏感性分析探索异质性的来源。结果 最终纳入文献6篇，均为队列研究，纳入支气管肺发育不良早产儿合计424例，同期正常早产儿合计1024例。Meta分析显示：与正常的早产儿相比，患有PDA的早产儿发生BPD的风险更高，差异有统计学意义（OR=1.49，95%CI：1.19~1.85，P＜0.05）；导管直径＞1.5 mm的PDA患儿发生BPD的风险是正常早产儿的1.75倍（OR=1.75，95%CI：1.20~2.53，P＜0.05）。结论 动脉导管未闭的早产儿发生支气管肺发育不良的风险高于动脉导管闭合的早产儿。同时，导管直径＞1.5 mm的PDA早产儿患支气管肺发育不良的风险更高。
Abstract:
Objective To clarify the relationship between the diameter of patent ductus arteriosus (PDA) and bronchopulmonary dysplasia (BPD) in premature infants.Methods The literature on the correlation between PDA and the risk of bronchopulmonary dysplasia was searched by searching PubMed, EMbase, Cochrane Library, Web of Science, CNKI, Wanfang and other electronic databases until October 2022. The quality of the included articles was evaluated, and the odds ratio (OR) and 95% confidence interval (95%CI) were calculated. RevMan5.4 software was used for data analysis, and I-Square (I2) test and sensitivity analysis were used to explore the sources of heterogeneity.Results Finally, 6 articles were included, all of which were cohort studies. A total of 424 premature infants with bronchopulmonary dysplasia and 1024 normal premature infants were included. Meta-analysis showed that compared with normal preterm infants, preterm infants with PDA had a higher risk of BPD, and the difference was statistically significant (OR=1.49,95%CI:1.19-1.85，P<0.05); the risk of bronchopulmonary dysplasia in PDA with ductus diameter >1.5 mm was 1.75 times higher than that in normal premature infants (OR=1.75,95%CI:1.20-2.53,P<0.05).Conclusion The risk of bronchopulmonary dysplasia in premature infants with patent ductus arteriosus is higher than that in premature infants with ductus arteriosus closure. At the same time, PDA preterm infants with catheter diameter >1.5 mm have a higher risk of bronchopulmonary dysplasia.

参考文献/References:

[1]Kalikkot Thekkeveedu R,Guaman MC,Shivanna B.Bronchopulmonary dysplasia: A review of pathogenesis and pathophysiology[J].Respir Med,2017,132:170-177. [2]Viscardi RM.Perinatal inflammation and lung injury[J].Semin Fetal Neonatal Med,2012,17(1):30-35. [3]Trembath A,Laughon MM.Predictors of bronchopulmonary dysplasia[J].Clin Perinatol,2012,39(3):585-601.[4]Carmichael SL,Kan P,Gould JB,et al.Maternal prepregnancy body mass index and risk of bronchopulmo-nary dysplasia[J].Pediatr Res,2017,82(1):8-13.[5]Schena F,Francescato G,Cappelleri A,et al.Association between Hemodynamically Significant Patent Ductus Arteriosus and Bronchopulmonary Dysplasia[J].J Pediatr,2015,166(6):1488-1492. [6]Brown ER.Increased risk of bronchopulmonary dysplasia in infants with patent ductus arteriosus[J].J Pediatr,1979,95(5 Pt 2):865-866.[7]Cokyaman T,Kavuncuoglu S.Bronchopulmonary dysplasia frequency and risk factors in very low birth weight infants: A 3-year retrospective study[J].North Clin Istanb,2019,7(2):124-130.[8]Clyman RI,Hills NK,Cambonie G,et al.Patent ductus arteriosus, tracheal ventilation, and the risk of bronchopulmonary dysplasia[J].Pediatr Res,2022,91(3):652-658. [9]Moher D,Liberati A,Tetzlaff J,et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement[J].PLoS Med,2009,6:e1000097.[10]Clyman RI,Hills NK,Liebowitz M,et al.Relationship between Duration of Infant Exposure to a Moderate-to-Large Patent Ductus Arteriosus Shunt and the Risk of Developing Bronchopulmonary Dysplasia or Death Before 36 Weeks[J].Am J Perinatol,2020,37(2):216-223. [11]Mirza H,Garcia J,McKinley G,et al.Duration of significant patent ductus arteriosus and bronchopulmonary dysplasia in extremely preterm infants[J].J Perinatol,2019,39(12):1648-1655.[12]Deng Y,Zhang H,Zhao Z,et al.Impact of patent ductus arteriosus shunt size and duration on risk of death or severe respiratory morbidity in preterm infants born in China[J].Eur J Pediatr,2022,181(8):3131-3140. [13]Sellmer A,Bjerre JV,Schmidt MR,et al.Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3[J].Arch Dis Child Fetal Neonatal Ed,2013,98(6):F505-F510. [14]Tauzin L,Joubert C,Noel AC,et al.Effect of persistent patent ductus arteriosus on mortality and morbidity in very low-birthweight infants[J].Acta Paediatr,2012,101(4):419-423. [15]Stang A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J].Eur J Epidemiol,2010,25(9):603-605.[16]Chang LY,McCurnin D,Yoder B,et al.Ductus arteriosus ligation and alveolar growth in preterm baboons with a patent ductus arteriosus[J].Pediatr Res,2008,63(3):299-302. [17]Hamrick SEG,Hansmann G.Patent ductus arteriosus of the preterm infant[J].Pediatrics,2010,125(5):1020-1030.[18]Coalson JJ,Winter V,deLemos RA.Decreased alveolarization in baboon survivors with bronchopulmonary dysplasia[J].Am J Respir Crit Care Med,1995,152(2):640-646. [19]Gerhardt T,Bancalari E.Lung compliance in newborns with patent ductus arteriosus before and after surgical ligation[J].Biol Neonate,1980,38(1-2):96-105. [20]Groneck P,G?觟tze-Speer B,Oppermann M,et al.Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates[J].Pediatrics,1994,93(5):712-718.[21]Herget J,Hampl V,Povysilova V,et al.Long-term effects of prenatal indomethacin administration on the pulmonary circulation in rats[J].European Respiratory Journal,1995,8(2):209-215.[22]El-Khuffash A,James AT,Corcoran JD,et al.A Patent Ductus Arteriosus Severity Score Predicts Chronic Lung Disease or Death before Discharge[J].J Pediatr,2015,167(6):1354-1361.e2. [23]de Carvalho Nunes G,Wutthigate P,Simoneau J,et al.Natural evolution of the patent ductus arteriosus in the extremely premature newborn and respiratory outcomes[J].J Perinatol,2022,42(5):642-648. [24]Semberova J,Sirc J,Miletin J,et al.Spontaneous Closure of Patent Ductus Arteriosus in Infants ≤1500 g[J].Pediatrics,2017,140(2):e20164258. [25]Rolland A,Shankar-Aguilera S,Diomandé D,et al.Natural evolution of patent ductus arteriosus in the extremely preterm infant[J].Arch Dis Child Fetal Neonatal Ed,2015,100(1):F55-F58. [26]Sankar MN,Bhombal S,Benitz WE.PDA: To treat or not to treat[J].Congenit Heart Dis,2019,14(1):46-51. [27]Ohlsson A,Walia R,Shah S.Ibuprofen for the treatment of a patent ductus arteriosus in preterm and/or low birth weight infants[J].Cochrane Database Syst Rev,2003(2):CD003481.[28]Mirea L,Sankaran K,Seshia M,et al.Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias[J].J Pediatr,2012,161(4):689-94.e1.[29]Clyman RI,Liebowitz M,Kaempf J,et al.PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age[J].J Pediatr,2019,205:41-48.e6. [30]Edstedt Bonamy AK,Gudmundsdottir A,Maier RF,et al.Patent Ductus Arteriosus Treatment in Very Preterm Infants: A European Population-Based Cohort Study (EPICE) on Variation and Outcomes[J].Neonatology,2017,111(4):367-375. [31]Sung SI,Chang YS,Chun JY,et al.Mandatory Closure Versus Nonintervention for Patent Ductus Arteriosus in Very Preterm Infants[J].J Pediatr,2016,177:66-71.e1.

相似文献/References:

[1]董显燕,高李华.BNP及NT-proBN诊断早产儿动脉导管未闭临床分析[J].医学信息,2019,32(12):70.[doi:10.3969/j.issn.1006-1959.2019.12.022]
　DONG Xian-yan,GAO Li-hua.Clinical Analysis of BNP and NT-proBN in the Diagnosis of Patent Ductus Arteriosus in Premature Infants[J].Journal of Medical Information,2019,32(18):70.[doi:10.3969/j.issn.1006-1959.2019.12.022]
[2]沙春娜,张海鸿.枸橼酸咖啡因治疗早产儿呼吸暂停及预防支气管肺发育不良的效果[J].医学信息,2020,33(02):142.[doi:10.3969/j.issn.1006-1959.2020.02.042]
　SHA Chun-na,ZHANG Hai-hong.Effect of Caffeine Citrate on Apnea and Prevention of Bronchopulmonary Dysplasia in Preterm Infants[J].Journal of Medical Information,2020,33(18):142.[doi:10.3969/j.issn.1006-1959.2020.02.042]
[3]饶 军,程贤高,李晓春,等.布地奈德联合肺表面活性物质气管内注入防治早产儿支气管肺发育不良的效果[J].医学信息,2020,33(23):147.[doi:10.3969/j.issn.1006-1959.2020.23.043]
　RAO Jun,CHENG Xian-gao,LI Xiao-chun,et al.Effect of Intratracheal Injection of Budesonide Combined with Pulmonary Surfactant in the Prevention and Treatment of Bronchopulmonary Dysplasia in Premature Infants[J].Journal of Medical Information,2020,33(18):147.[doi:10.3969/j.issn.1006-1959.2020.23.043]

更新日期/Last Update: 1900-01-01